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ABSTRACT
INCREASING ACCESSIBILITY TO MONITORING AMMONIA LEVELS IN THE
BODY THROUGH DEVELOPMENT OF A NOVEL POINT-OF-CARE BREATH
AMMONIA DIAGNOSTIC DEVICE
(Under the directions of Troy Drewry)
Hyperammonemia is a life-threatening metabolic condition that is characterized
by elevated levels of ammonia concentrations in the blood. Resulting from serious
conditions such as chronic kidney disease or liver failure, the limited functions of the
liver and kidney lead to an increase in blood urea nitrogen (BUN) within the body.
Currently, there are a wide variety of treatments for this condition, ranging from various
medications to surgical procedures such as liver transplants. However, there is a lack of
variety in diagnostic testing methods to determine a patient’s ammonia levels. In most
cases, patients will need to schedule a doctor’s appointment to perform a blood test;
blood samples are sent to a lab to then be analyzed for ammonia concentrations. Though
this method is sufficient, it is often extremely complicated, costly, and time-consuming.
Moreover, patients with hemophobia or sensitivity to being pricked often find this testing
procedure extremely uncomfortable. Thus, our biomedical engineering senior design
team sought to develop a non-invasive screening device that detects ammonia in
real-time. There is a reasonable correlation between blood urea concentration and
mouth-exhaled ammonia concentration. The device contains an ammonia sensor that
allows for the detection and display of ammonia levels through mouth exhalation. This
sensor, when in the presence of ammonia, rises in conductivity along with the rising gas
concentration. With the device, a detailed instruction pamphlet will be included which
will provide safe operating instructions for the user. The device is currently in
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development as proof of concept. With sufficient funding, resources, and research the
potential for more accurate detection sensors is viable.
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Introduction
Part of the degree requirements for Biomedical Engineering includes taking a
two-semester sequence during senior year which consists of Senior Design I and Senior
Design II. In Senior Design I, all students are tasked with finding 3 clinical needs and
then pitching them to the class. Four of these clinical needs were chosen, and then the
class split up into teams to start researching and brainstorming to solve these problems.
When trying to find unmet clinical needs, many students asked family and friends
what bothered them or what would make their lives easier when receiving medical
treatment. As it turns out, one of our family members, who is a four-year-old female, was
in and out of the hospital for a couple of months before being diagnosed with a urea cycle
disorder (UCD). This is a genetic disorder where the body can not convert ammonia into
urea, thus creating a build-up of ammonia. While there are certain medications and diet
plans she can follow to keep ammonia levels suppressed, any imbalance in diet,
medication, or behavioral activity can trigger higher levels of ammonia and this can occur
for the rest of her life. To ensure ammonia levels stay in a safe range, blood has to be
drawn every two weeks or a month depending on where previous levels fell. Due to the
blood having to be drawn and prepared in a specific way to ensure correct results for
certain tests, this testing has to be done in a hospital setting where the test can be run
quickly or properly separated and stored to be sent off to a lab where results normally
come back in a week. This is very inconvenient not only because she doesn’t like needles
but also because by the time the test results come in, levels could have increased even
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more. This current process does not provide a satisfactory way to measure ammonia
results in real-time because there have been times in between bloodwork appointments
when she has had to go to the emergency room to get treated for hyperammonemia which
is where ammonia levels have exceeded the upper limit of the normal range. As a result,
she has had to get IV infusions and in extreme cases hemodialysis to remove the excess
ammonia from her system. Had the increase of levels been caught earlier while they were
still low enough to decrease them by adjusting diet and medication from home, it
probably would have prevented the hospital visits for hyperammonemia. Because of the
difficulties facing the four-year-old female and her parents, the idea to create an at-home
ammonia diagnostic device came about so that easily monitoring levels to provide
adequate treatment when needed would be available.
Our device, Ammonia-lyzer, aims to increase accessibility to monitoring
ammonia levels in the body through the development of a novel point-of-care breath
ammonia diagnostic device. Throughout this two-course sequence, we have been
developing this product through researching the disease state of hyperammonemia,
current diagnostic methods and those in development, the problems with the current
diagnostic options, and the market potential. Hyperammonemia, if not treated quickly,
can cause irreversible brain damage and even death. If patients aren’t getting accurate
ammonia levels in real-time, levels can increase over time in the background and trigger
one of these hyperammonemic episodes. In an effort to prevent hyperammonemic events
from occurring, we developed Ammonia-lyzer: a breath ammonia diagnostic device that
allows more convenient and frequent testing to be performed in the home while being
less invasive than traditional blood ammonia testing performed in hospitals.
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What is Hyperammonemia?
Ammonia is produced naturally as a result of the breakdown of amino acids in the
colon, small intestines, and skeletal muscle. While it is naturally produced, in high
concentrations, ammonia is extremely toxic. After it is produced, ammonia is then
transferred to the liver where it gets converted into urea, which is a less toxic chemical,
by way of the urea cycle. The kidneys are then able to easily excrete the urea in the urine
due to it being water-soluble [1]. If any step in this process is interrupted or unable to be
carried out, it can lead to abnormally high levels of ammonia that exceed the normal
physiological range. As a result, detrimental and irreversible neurological effects and
even death can occur. When plasma ammonium levels are elevated to levels outside of
the normal physiological range, the resulting effect is called hyperammonemia [2].

What Levels are Considered Hyperammonemic?
When ammonia levels initially increase in the body, glutamine is produced in
other organs to briefly protect the body from the toxic effects of ammonia. In addition,
more ammonia is temporarily excreted in urine which allows for less absorption into the
blood. Unfortunately, these protections do not last long as hyperammonemia becomes
more severe [3].
Different age groups have varying ranges of standard blood ammonia levels.
Infants from age 0 to 14 days have a range of levels of 56-107 µmol/L. From the age of
15 days to less than 2 years old, the standard range is 40-80 µmol/L. Children and adults
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older than 2 years show between 11-35 µmol/L as being normal. The lab starts providing
courtesy alerts if results go above 80 µmol/L [4].
Breath Ammonia levels in a normal individual have a range from 50 to 2,000
parts per billion (ppb) [5]. A scientific study that tested the correlation between ammonia
levels and protein intake by using both breath and blood ammonia testing, discovered that
mean breath ammonia ranged from 490 to 704 ppb at baseline and from 920 to 1642 at
maximum. Meanwhile, mean blood ammonia ranged from 107 to 171 μg/dL at baseline
and from 218 to 342 μg/dL at maximum levels [6]. By converting the breath ammonia
reading from ppb to μg/dL the levels ranged from 49 to 70.4 μg/dL at baseline and from
92 to 164.2 μg/dL at maximum. The blood ammonia levels are around 2.25 times higher
than the breath ammonia levels.

What Conditions Cause Hyperammonemia?
While hyperammonemia is a symptom of many conditions, such as genetic
defects in the urea cycle, hepatic damage or disorders, and kidney failure, if left
unrecognized and untreated immediately, significant damage can occur. While
hyperammonemia occurs as a symptom of many disease states, genetic defects in the urea
cycle disorder lead to the most severe cases of hyperammonemia [7].

At What Age Do Hyperammonemic Episodes First Occur?
In a study from 1983 to 2003, researchers followed 260 patients for 21 years and
over that time, there were 975 instances of hospitalization where an injection of
NaPA/NaBZ Injection 10%/10% as a treatment to control a hyperammonemia episode.
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While this study was for the FDA regulatory process of the drug Ammonul®, which is
included in many emergency treatments for hospitalizations now, it provides a good
overview of the frequency and severity of hyperammonemic episodes in patients with
UCDs. Of the 260 patients in this study, this is the breakdown of when the first
hyperammonemia episode was experienced: 34% were 0-30 days old, 18% were 31 days
to 2 years old, 28% were 2 to 12 years old, 10% were 12-16 years old, and 10% were 16+
years old. The age range was 1 day to 53 years and the median age was 2 years old [8].
Figure 1 shows the number of participants in this study characterized by UCDs diagnosis.
The data is further broken down to include the age of their first hyperammonemia
episode.

Why Do Hyperammonemic Episodes Reoccur After Diagnosis of Initial Disease?
Many children that have UCDs can have a hyperammonemia episode at any point
in their life due to an imbalance in nitrogen. Increased intake of protein, prolonged
fasting, a fever, or increased exercise can trigger a hyperammonemia episode [9].
Therefore many children with UCDs have a special diet plan and list of medications
created by a dietician and doctor to try to keep ammonia levels at bay. An example of
such a plan can be found in Appendix A. However if this plan isn’t followed as
prescribed, events can be triggered. 58% of all hyperammonemic episodes had a reported
illness prior to the episode. Additionally, 15% were due to not following the prescribed
diet which could entail receiving too much high protein or too few calories. 10% were
due to non-compliance with medication which could entail missing a dose of medication
or not taking it at the prescribed time. Finally, 10% of the hyperammonemic episodes
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were due to major life events such as school stress, surgery, or accidents [8]. Because of
the variety of factors that can trigger a hyperammonemia episode at any time, it is
especially important to monitor ammonia levels in UCD patients to intervene with
treatment before levels get too high that symptoms of a hyperammonemia episode occur.

Figure 1: Number of patients by diagnosis and age at first episode [8]

Frequency of Hyperammonemic Episodes
While previously mentioned that hyperammonemic episodes hail from a
multitude of disorders, it is hard to get an accurate picture of how many episodes actually
occur each year. Around 1 in 35,000 people on average are born each year with a urea
cycle disorder [10]. According to the Center for Disease Control, in 2020 the birthrate
was around 3,613,000 in the United States (US) [11]. That comes out to around 103
people born with UCDs each year just in the US alone. In the 1982-2003 study, many
patients experienced multiple episodes of hyperammonemia over a period of 21 years.
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For patients that experienced 5 or more episodes throughout the 21 years of this study, the
average number ranged from 2.2 to 2.8 depending on the specific UCD the patient had
and the sex of the patient. The range of episodes per year varied from 0.6 to 8 episodes
per year. For males with UCDs around 70% of hyperammonemia, episodes happened
between 31 days and 12 years while in females 92% of episodes occurred between 2 and
12 years old [8].
Figure 2 shows the number of episodes documented in this study characterized by
UCDs diagnosis. The data is further broken down to include the age of the patient at the
time of the hyperammonemic episode.

Figure 2: Number of patients by diagnosis and age at the time of episode [8]

Symptoms of Hyperammonemia
Many of the symptoms associated with hyperammonemia are neurological since
ammonia is toxic to the brain but not to other tissues in the body [3]. 80% of episodes
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documented a neurological symptom, and 33% of episodes documented gastrointestinal
symptoms [8]. Some of the symptoms of hyperammonemia include vomiting and
lethargy, but the most concerning effect if this is left untreated is brain damage or even
death [12]. Many of these symptoms develop slowly over a few days going from
vomiting and lethargy to disorientation and coma if not treated [3]. The symptoms of
such a disease range with the age and level of ammonium. Infants normally show poor
suck, hypotonia, vomiting, lethargy, grunting respirations, and seizures. Older children
normally present a range of symptoms from behavioral changes to a frank coma. It is
generally harder to diagnose because a lot of the symptoms are nondescript such as
vomiting, headache, increased respiratory rate, and poor appetite are confused with other
problems [12].
Children with Urea Cycle Disorders (UCD) who have survived several
hyperammonemic episodes show focal cortical necrosis and ventriculomegaly and can
even have deficient myelination. The severity of these effects corresponds with the length
of the hyperammonemic events [2].

How Are Hyperammonemic Episodes Treated?
When treating hyperammonemia, the goal is to correct imbalanced biochemical
levels and reinstate proper nutritional intake. Patients with UCDs normally have an
emergency treatment plan, developed by their doctor, on the steps to take in the event of a
hyperammonemia episode, which is when levels reach 3 times the reference range [13].
A standard treatment plan is listed in Appendix B. The first step of this treatment is to
immediately stop protein intake and consult with the doctor and the dietician. Many times
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if the episode is caught early, this step can reverse the ammonia build-up without hospital
intervention. Step 2 is to provide intravenous fluids, D10W+NS to provide calories [14].
If hyperammonemia is confirmed by a blood ammonia test, the next step is to give
Intralipid which provides calories and essential fatty acids for nutrition [15]. Next,
ammonia scavenger medicines including sodium benzoate, arginine, phenylacetate, and
phenylbutyrate are used to remove the nitrogen by transforming it into other products that
can be excreted [1]. After the administering of the ammonia scavenger medications, the
ammonium levels in the blood should be checked in addition to every 8 hours. If the
levels do not decrease in 8 hours, hemodialysis should be started to rapidly dispose of
ammonia and other nitrogenous wastes. Newborns with a standard of levels higher than
300 µmol/L should be immediately administered hemodialysis; however, in older
patients, there is no ammonia level cutoff that has been established. Therefore, clinical
judgment is to be used.
The current therapeutic options to treat hyperammonemia focus on targeting
either the reduction of ammoniagenesis and its rate of absorption in the GI tract or by
activating ammonia removal by upregulating ureagenesis through treatment with
N-carbamylglutamate or supplementing with urea cycle intermediates and glutamine
synthesis [16]. Front-line therapy options for patients are primarily nonabsorbable
disaccharides. The most prevalent example is the complete metabolization of lactulose
into lactic, formic, and acetic acid in the colon by B-galactosidase from colonic bacteria.
This causes increased acidification in the colon and osmotic pressure, thus inhibiting the
growth of urease-active bacteria. Rifaximin is currently the most effective antibiotic in
treating hyperammonemia. A nonsystemic, GI site-specific antibiotic, Rifaximin results
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from adding a nonabsorbable pyridoimidazole ring. However, it still retains the potential
to cross the cell wall of Gram-negative bacteria and inhibits RNA synthesis by binding to
the B subunit of the bacterial DNA-dependent RNA polymerase enzyme. Table 1
explores current various treatment options [16].
These various treatment options are the most commonly available to patients in
need. However, these options also reveal a more concerning picture - the lack of
affordable and readily available treatments. Most medicines do not cure
hyperammonemia, they rather serve as long-term options that must be taken daily. For
example, peritoneal dialysis requires patients to set aside three to five hours for treatment
per week for approximately $53,000 [17]. Permanent treatments such as liver transplants
are also incredibly expensive. The estimated mean cost of a U.S liver transplantation was
approximately $163,438 [18].
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Table 1: Current Treatments of Hyperammonemia [16]
Names of
Medicines

Pharmaceutical
Name

Mechanism of Action

Drawbacks

Lactulose

Enulose

Acidification of colonic
contents, increase in
osmotic pressure, cathartic
effect

Abdominal
cramping, bloating,
flatulence,
electrolyte
imbalances

Rifaximin

Xifaxan

Inhibition of RNA
synthesis in intestinal
bacteria.

High cost, nausea,
bloating, diarrhea

Sodium
Benzoate

Ammonul

Decrease glycine
degradation, increase
glycine elimination

Headache, nausea,
impaired mental
status

Sodium
phenylacetate/
phenylbutyrate

Bupenyl

Decrease glutamine
degradation, increase
glutamine elimination

Complication for
patients with
hypertension

L-arginine/L-ci
trulline

L-arginine/
L-citrulline

Activation of UC

Gastrointestinal
distress, diarrhea

Carglumic
Acid

Carglumic Acid

Activation of UC through
N-acetylglutamate
restorement

Chills, body aches,
flu symptoms, sores
in mouth and throat

Albumin-based
dialysis

Prometheus,
Hepa Wash,
MARS

elimination of
albumin-bound substances

mild
thrombocytopenia

Peritoneal
dialysis

Peritoneal
dialysis

decrease of blood ammonia
by transporting ammonia
from vascular system to
peritoneal cavity

mild to moderate
nausea and
vomiting

Neomycin

Neomycin

inhibition of protein
synthesis in intestinal
bacteria
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oto-, neuro-,
nephrotoxicity

Diagnostic Methods and Shortcomings

Traditional Diagnostic Methods and Problems
Plasma ammonia levels are needed to diagnose or confirm hyperammonemia, but
getting an accurate reading is a challenge sometimes. The standard current practice is
based on the method of the amino reduction of alpha-ketoglutarate. This method requires
a reduced nicotinamide adenine dinucleotide phosphate (NADPH). While this method is
an indirect method of measuring ammonia, the reduction of the a-ketoglutarate is
proportionally correlated with the amount of ammonia in the blood. Spectrometry is used
to measure the concentration of the alpha-ketoglutarate [19].
While the method of using amino reduction of α-ketoglutarate is the standard
method used in laboratory analysis, it does have many limitations. One of which is the
collection and handling of the sample. Because this blood is not tested immediately, it has
to be venously collected [19]. For this method to yield accurate results, the blood samples
must be taken in a 3 mL lavender-top (K2 EDTA) tube [4], which is shown in Figure 3.
Additionally, the sample must be taken without using a tourniquet or clenching
the fist because muscle contractions normally elevate ammonia levels taken from a vein.
If these collection procedures are not followed, the results will be invalid. However, the
collection of the sample is not the only source of error. Because ammonia is stable for
less than 15 minutes at 4 C°, samples must be immediately put on ice and the plasma
must be separated from the cells within 15 minutes and then frozen immediately. The
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specimen is not allowed to sit at room temperature or even be refrigerated. If the sample
is not frozen or received somewhat partially thawed, the test will be rejected [20].

Figure 3: 3 mL lavender-top K2 EDTA tube

Smaller laboratories that might not have the correct equipment or methods to
handle the sample, use a faster and cheaper method. This method involves putting whole
blood on a dry chemistry strip that contains bromocresol green. The level of ammonia is
measured by reacting bromocresol green and measuring the range of color. However, if
levels are above 286 micromol/L the results are unreliable.
Due to the mishandling and delay of the samples before testing, many tests come
back with increased false levels of ammonia. If mishandling is suspected, the test has to
be run again.
Currently, testing the blood for ammonia typically involves drawing the blood
from a vein, transporting the sample cold-stored to a lab, then waiting hours for the
sample to be centrifuged and subjected to a biochemical assay. Furthermore, the testing
process can often be inconclusive, resulting in more samples to be taken and analyzed.
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As such, this invasive time-consuming procedure can be an unnerving experience for
patients who are uncomfortable with drawing blood.

Diagnostic Methods in Development and Problems
As diagnostic methods are being investigated for more non-invasive procedures,
testing the measurement of ammonia in exhalation is gaining traction. Helicobacter
Pylori (HP) is a bacteria that lives in the stomach. HP will secrete the urease, which will
split urea into carbon dioxide and ammonia [21]. Currently, the standard and most used
breath test is the C13 urea test. C13 is a rare but natural isotope of carbon dioxide; there
is no urease in uninfected humans, so detection of urease activity is an indication of an
HP infection. When testing, a patient is given a small amount of urea by mouth, which is
marked with C13. The carbon dioxide produced by urease will then also be marked by
C13, thus indicating individuals with C13. This is a basis for modern ammonia breath
testing, which instead focuses on detecting the ammonia rather than the carbon dioxide
[22]. Thus, the availability of a completely noninvasive breath testing methodology
provides a straightforward alternative for detecting ammonia levels.
Other diagnostic tests are being researched and improved to lessen the
invasiveness. For example, researchers at Stanford are developing a glucometer-like
device for measuring blood ammonia which can be seen in Figure 4. Reimagining the
traditional ammonia gas sensor, it is paired with test strips that can isolate ammonia from
the blood once dabbled with capillary blood. The device also measures and reports the
levels in less than a minute while only requiring one drop of blood, which is almost less
than 1 percent of the blood required for a standard lab test [23]. However, this device is

14

still in development and is not available to the market yet. In addition, while it is less
invasive than drawing blood venously, it is still somewhat invasive in that a finger still
has to be pricked.

Figure 4: Stanford startup blood ammonia reader

Current At-home Ammonia Diagnostic Devices “On the Market” and Problems
The primary issue underlying “at home” diagnostic options for ammonia levels is
ultimately the lack of available, cost-effective devices. For example, PocketCHEM BA
Blood Ammonia Analyser, developed by Woodley Laboratory Diagnostics [24], is a
portable blood ammonia measurement device that enables immediate testing and delivers
results in approximately 3 minutes and 30 seconds. An image of this device can be seen
in Figure 5. However, it is not readily available for purchase for residential or private use,
only being permitted in hospitals, pediatric units, healthcare settings, and laboratories.
Additionally, it is only available in certain countries. With these devices only available
commercially and limited, they are often far too expensive at a cost of $3,000 for an
everyday user to obtain.
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Figure 5: PocketCHEM BA [24]

Ultimately, in the medical industry, breath ammonia monitoring is extremely rare
due to the high costs and complexity associated with the detection instruments. Currently,
a device named AmBeR, which can be found in Figure 6, is being developed for use in
both clinical and home settings. This device will consist of a new ammonia sensing
material, polyaniline, a sensitive-to-ammonia conductor of electricity that can be
deposited on the device using low-cost printing methods [25]. However, it is still in
testing and development and the availability of AmBeR is still unseen in today’s markets.
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Figure 6: AmBeR by BreathDX
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Design and Development Process for Ammonia-lyzer

Literature Review
After discovering this unmet clinical need for creating an at-home ammonia
diagnostic device (Ammonia-lyzer) so people who were predisposed to having
hyperammonemic episodes could routinely monitor their ammonia levels, the next step
was to perform a literature review. The literature review that was performed can be found
in Appendix C. This document focuses on five areas which include the disease state, the
current diagnostic options, the user needs, market research, and the competitive
landscape. This document provides much of the foundation for the rest of the project.
While the disease state and current diagnostic options have been explained in
depth in previous sections of this document, we will now focus on the unmet user needs.
Since ammonia levels build up over time and symptoms severity increases with levels, it
is important to provide a point-of-care option to people that have a predisposition to
hyperammonemic episodes, such as those with UCDs. Because a hyperammonemia
episode can be triggered by subtle changes in diet, exercise, or even stresses in these
patients, it is important to be able to monitor the levels of ammonia frequently to assess if
changes to any of these areas increase levels so that an increase in levels can be caught
and addressed before symptoms progress so where hospital intervention is needed or so
that adjustments to lifestyle can also be made to prevent hyperammonemic episodes in
the future. One of the unmet user needs is easier accessibility. A more convenient
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option to get ammonia results is needed instead of having to travel to a hospital that has
the ability to correctly take the sample and correct equipment to run a test. To get blood
tests done, the four-year-old female family member and her mother have to go to
downtown Houston which is an hour both ways from where they live. After a
hyperammonemia episode or changing any part of her medication or diet, her levels have
to be monitored every 2 weeks until another change in medication or diet or the labs look
good. In addition, if all is well, testing transitions to monthly. From the period of
December to mid-March they were getting blood tested every 2 weeks. Therefore, that is
an average of about 15 hours not to mention the amount of time in the doctor's office
every time her levels need to be monitored. While the female family member diagnosed
with a UCD is only 4, in August she will be going to school, and it will be much harder
for her to get those tests done to monitor levels. Additionally, traditional ammonia testing
normally reports results about a week after the sample is sent to the lab. However, by
then, levels could have drastically changed. Therefore faster testing coupled with
convenient testing places are needed to get an accurate level count. Another user need is a
less invasive option. Many UCD patients are children who are growing so their
medication amounts and diet changes are changing frequently. This means that they are
getting many blood ammonia tests taken. If the child does not like needles, which many
of them do not, it can be a challenge to get a venous blood sample which is required for
the traditional ammonia tests. To summarize, some of the preliminary user needs we
found included better accessibility, faster response and reporting time, and a less invasive
way to get the measurement. This device should be useful to parents who have children
who are more susceptible to higher ammonia level diseases and disorders. An at-home
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blood ammonia checker would allow caregivers and parents to be able to monitor their
child’s ammonia level without bringing them into a clinic, and this would help diagnose
rare genetic disorders or other potential disorders due to a high ammonia concentration
within the blood.
The next thing that was looked into was market research. Around 140 million
people were born in 2020 [26]. By using the 1 in 35,000 UCD births per year, that is
around 4,000 people born each year that will at some point in their lives need to monitor
their ammonia levels. Over the past 20 years, that is around 60,000 people that need to
monitor their levels worldwide. While we are designing this device with UCD patients in
mind, the opportunity for this device to measure ammonia in other contexts is vast. While
this device would primarily be used to prevent hyperammonemic events and provide data
to the patient on how their changes in medication and diet as prescribed by a doctor are
affecting their ammonia levels, there are many more implications. This device could in
the future be used to monitor the effectiveness of hemodialysis, assess asthma, diagnose
hepatic encephalopathy, detect Helicobacter pylori, and analyze halitosis [5]. There could
also be sports training applications in exercise physiology and studies of drug metabolism
[27]. All of these applications lead to an ever-growing market of at-home ammonia tests.
Blood ammonia tests are most prominent in the medical field and have been
widely used in hospitals and doctor offices. Companies have started creating portable
blood ammonia checkers that would allow patients to be able to check their ammonia
levels. PocketChem can produce results in up to 3 minutes and 20 seconds. For blood
ammonia-related purposes, PocketChem has been the top provider for patients and
hospitals. But, its uses are typically for doctors' offices, health clinics, hospitals,
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laboratories, military settings, etc. [24]. AmBeR is another device created by BreathDX
that measures the ammonia levels of your breath [28]. A new prototype for a blood
ammonia checker is being created by Dr. Chu, which guarantees results within a minute.
It uses a chemical process to isolate ammonia from the blood. This new device needs a
single drop of blood to detect and measure ammonia levels in the blood using an
integrated sensor. However, the device is still in prototype form [23]. Ultimately, while
there are options available, currently they are extremely expensive and still in prototyping
phases. Nonetheless, a vacuum exists for a portable blood ammonia reader that can be
affordably obtained and simplistically used in the comfort of a patient's home.

Prior Art Search
After completing the Literature Review, the next step in our process was to
conduct a search on prior art. The Prior Art document can be found in Appendix D. This
task consisted of going through and finding both US and international patents to see what
devices were out there that had qualities that we wanted to in some way mimic in our
design. All of the initial prior art searches were for blood ammonia testing. These
searches yielded several patent applications for blood ammonia detection. Patents such as
US10591495B2 [29] and US9625443B2 detailed methods for rapid detection of blood
ammonia and/or hyperammonemia. Patent US9625443B2 is the patent from the Stanford
research group that partnered with Aza Technology. Schematics for this device can be
found in Figure 7 and Figure 8. Figure 7 represents the standard industrial ammonia
sensor they purchased for around $200. Figure 8 shows the schematic of the blood
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ammonia device with label 14 representing the sensor while label 12 represents where the
blood sample area resides. [23]

Figure 7: NH3 sensor used in Stanford startup blood ammonia reader [23]

Figure 8: Internal schematic of Stanford startup blood ammonia reader [23]

These patents often used alkali buffer solutions and reagents that required blood
or body fluid samples. Various other international patents often revealed a similar
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methodology. While the device patents were impressive in their technology, we wanted
our device to be completely non-invasive and found that the feasibility of developing a
minimally invasive device with similar chemical technology was outside the scope of our
budget and resources. Further research into potential non-invasive detection methods
highlighted a relatively obscure diagnostic option which included detecting ammonia
from human breath exhalation. Upon switching our main focus to breath ammonia, we
found several patent applications for methods and apparatuses for detecting ammonia
from exhaled breath. For example, US Patent 20050171449A1 [30] details an apparatus
for detecting ammonia in exhaled breath through a breath capture device that contains a
selected Lewis acid dye, which when deposited produces a detectable spectral or
reflectance response in the presence of ammonia. As shown in Figure 9, this apparatus
would be connected to a computer and receive the breath-component signals from the
analyzer, and memory and data programs in the computer would store the signals and
provide a response for the patient based on the correlating inputs.

Figure 9: U.S Patent 20050171449A1 [30]
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Design and Development Plan
After conducting the prior art search, the next step in the design process was to
form the design and development plan which can be found in Appendix E. This
document touches on the problem, a needs statement, literature review, prior art search,
competition and differentiation, value proposition, the anticipated regulatory pathway,
reimbursement strategy, estimated costs, potential market impact, indications for use,
patient population, materials, features, and components. This document consisted of
putting all of our previous work into one document as well as adding additional
considerations.
While the problem, literature review, and prior art search have previously been
covered in-depth, we will move on to the major competition and what we initially
decided would differentiate our product. BreathDX would be considered our main
competitor since they have developed a breath ammonia detection device called AmBeR,
which can detect the content of ammonia in just eight breaths. The device uses a
glucose-like test strip which is inserted into the device and comes into contact with
polyaniline to measure the ammonia found. For our prototype, we plan to have an
easy-to-use, portable, cheap blood ammonia test that differs from our competitors. Our
prototype will include a tube, in which you exhale through your mouth. This will then
lead into a small box that encompasses the gas sensor that will detect the concentration of
ammonia found within the exhalation. In the presence of ammonia, the sensor’s
conductivity will increase with correlation to the increase in the gas concentration. The
device will have a built-in circuit that will allow for the readings of the changes in

24

conductivity which will then display an approximate ammonia concentration reading on
an LCD screen. The sensor reads in parts per million (ppb) but the output from the sensor
can be converted through formulas in the code to the standard measurement of ammonia
which is µmol/L. By using a common gas sensor instead of expensive equipment that is
normally found in a lab, we are creating a device that people can afford to monitor their
or their children’s ammonia levels even if insurance does not decide to pay for the device.
When constructing the Design and Development Plan, we also looked at what
value our device would have to consumers. An at-home breath ammonia reader such as
Ammonia-lyzer will allow people to test ammonia levels in the comfort of their home.
The idea of transitioning testing from hospital to home allows patients a point-of-care
option to address treatment similar to the way a glucometer measures blood sugar. As a
result of instant results, treatment action can be taken immediately if needed. Instead of
waiting long times for lab samples, patients can accurately get their ammonia level in
minutes. This would provide patients with a “video” of health of where ammonia levels
are instead of giving them a “photo” of health once every two weeks. This would also
provide peace of mind to consumers since ammonia buildup can cause serious side
effects if not caught.
As with any medical device, eventually, the plan would be to apply for FDA
approval. The class of this device is anticipated to be a Class II device, similar to the
diagnostic device of a non-invasive glucometer. The regulatory pathway we plan to
pursue is the 510k submission process. This will expedite the process in which the FDA
reviews the application and shouldn’t require a clinical study.
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While it was mentioned that the goal is for this product to be affordable for
patients even if insurance decided not to pay for it, we do plan to use the cost-based
reimbursement strategy. This states that the payer will agree to reimburse the provider for
the costs incurred in providing services to the population. After trying to find the cost of
an ammonia test online we came across a test for $59 at both Quest and LabCorp [31]. If
a patient were to take a test at least every month for a year and maybe 6 additional tests to
monitor changing medications, the 18 tests per year would cost around $1,062 per year.
This device would be a preventative diagnostic tool to help monitor levels and detect
changes rapidly to try to prevent hyperammonemic episodes. After being hospitalized for
a hyperammonemic episode last year for three days, the four-year-old female family
member racked up a bill of $200,000 that luckily was billed to insurance. We plan for the
insurance companies to see the value of this device as a preventative care option to
reduce reactive care costs. In addition to being available for home and private use, we
aim to bring our product to the medical world in the future in which medics, physicians,
hospitals, and alike will utilize the product to provide more options in where patients can
get tested.
Our device will be marketed towards everyday people who can use this device
from the safety of their own homes to check their ammonia levels. Children and infants
have higher abnormalities in their ammonia levels. Because of this, it would be useful to
parents who have children who are more susceptible to hyperammonemic events. An
at-home blood ammonia checker would allow caregivers and parents to be able to
monitor their child’s ammonia level without bringing them into a clinic. This would help
form treatment plans to adjust medication and diet while also alerting when levels rise to
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a threshold that could trigger a hyperammonemic episode. In the future, it could be used
to test for rare genetic disorders such as UCDs at birth since it is a non-invasive and fast
option. It could also be used to measure the effectiveness of hemodialysis. Around
750,000 people live with kidney disease in the United States and while this accounts for
1% of Medicare's patients, the dialysis costs that these patients receive account for
around 7% of the total Medicare budget. This contributes to around $28 billion annually
[32]. While most of these markets are potential markets to tap into, we do plan to focus
on patients with UCDs where frequent monitoring is significantly needed. At the
moment, we will initially launch in the United States before reviewing plans for a global
launch due to varying international medical restrictions.

Design Summary Matrix
After developing more of the design features and business considerations of our
device and how those would set us apart from our competitors, we came up with and
more formally defined the user needs in the Design Summary Matrix document, which
can be found in Appendix F. We found seven primary user needs to keep in mind when
designing our product. The list is as follows: portable, safe, accurate, affordable, easy to
use, repeatable results, comfortable, and long-lasting.
With each of these needs, we went through and defined what the design input and
output would be for each need. Testing methods were also considered to verify and
validate the product. Verification activities would be performed to make sure the device
measures the values we want it to, but validation activities would also need to be
performed to ensure that the measured value is, in fact, the correct thing to measure.
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When designing the Ammonia-lyzer to meet the first user's need for portability,
we decided to make the device small enough to transport. We defined this as being no
bigger than the size of a tablet so that it can be transported easily and can be taken on
longer trips. Since creating the device and developing our prototype, the design has
transitioned into the size of a 6”x 6” cube. All of the electrical components fit within this
6” x 6” profile of the box.
Safety is something else that was considered when designing the Ammonia-lyzer.
Since electrical components will be utilized, there needs to be adequate grounding to
ensure there is no electrical shock to the user if any part in the circuit shorts. To test the
safety of the device, the plan is to put the device through rigorous testing after
prototyping to ensure we find failures before releasing the product. To further evaluate
the safety of our device and eliminate the failures through design efforts, we performed a
Risk Analysis Plan and a Failure Mode Effects Analysis (FMEA) document both of
which will be discussed later.
Since this device is a diagnostic monitoring device, accuracy was defined as the
third user need. The main component that would test this is the actual reading of the gas
ammonia sensor. Because hyperammonemic episodes are treated at three times the
normal levels, we decided the device needs to be accurate to ± 10 µmol/L to accurately
show the changes due to lifestyle changes and so that changes that could trigger a
hyperammonemic episode could be monitored and recorded. To verify that the levels are
accurate, future testing would include having varying known concentrations of ammonia
in a gas form and flowing it into the device. This will show if the sensor reads what the
actual concentration of ammonia is in the air. Validation on the other hand would require
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clinically testing breath ammonia on the device and getting those levels while also getting
blood tested the traditional way to ensure that the levels match. Of course, breath
ammonia and blood ammonia calculations are different but the correlation calculations
that we use in determining the blood ammonia from the breath can be checked to ensure
the levels are equivalent.
The fourth user need was affordability. As previously mentioned, the device needs
to be affordable to the average person. The cost of the device to the consumer after
reimbursement by the insurance company is intended to be less than $500. Therefore, we
intend to use standard common materials that are easily accessible and aren’t expensive.
As of right now, the ammonia gas sensor is the most expensive of all the parts we have
ordered at $34.95. In total, we have spent around $120 for the prototype; however, this
cost should be much less because we will not be using all of the parts that we initially
ordered. There are problems with the sensor that will be discussed later, but for now, a
new sensor with a smaller minimum detection limit is needed. Prices for the intended
new sensor are much more expensive at $687. However, this sensor might not be needed
if another design route with chemical test strips where a regular gas ammonia sensor
could be used is considered. This would put us more in line with competitors as far as
detection methods. By getting insurance to pay at least half of the cost and ensuring that
the consumer pays no more than $500 with insurance, $1,000 per device could be
charged. If the desired profit margin is 35%, $650 is available for the cost of the device.
In the future, if this device was to be mass-produced, the costs of material would be
cheaper due to economies of scale.
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Because this device will be used in homes, it is imperative that the device be easy
to use. The consumers that will be using this device do not have medical device training,
and thus can not be expected to provide inputs other than their external breath into this
device. This means that the device will need to prompt the user as much as possible to
complete the next steps. To satisfy the ease of use, users need a training manual that can
be read in less than five minutes. This would be provided when this product is released to
the market. To verify this user need, we will provide labels on the device and create the
training manual to allow the user to be aware of how to work the device. To validate this
need, field studies with users unfamiliar with the device could be conducted. The
measurement of this test would be to have them assess the ease with which they were
using the device.
Additionally, because this device will be used in homes and with many young
children it is extremely important for the device to be comfortable. We defined this as
minimally invasive. To satisfy this requirement, the initial idea mimicked a glucometer
using a drop of capillary blood to detect ammonia amounts. However, a less invasive
technique was considered, and it was decided to test ammonia by exhalation of the
breath. No child enjoys being stuck with a needle even if it’s just a prick in the finger.
Over time, if levels were being tested every day or two, it’s much easier to breathe into
the device than to have to prick a finger. Additionally, this option doesn’t involve
biological waste such as blood, which might ease user hesitations in handling this fluid.
The final user need that was determined was the ability for the device to be
long-lasting which means being able to be reused. Customers don’t want to shell out
money for a new device every time they need a test. With this need in mind, a sensor with
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a reliable life span of 200 tests, which would allow a test every other day for a little over
a year, was chosen If tested less frequently, the sensor would last even longer. In
addition, a rechargeable battery was used so regular batteries would not be an additional
expense. The goal of these reusable design features is to ensure that parents are not
spending unnecessary amounts of money. To verify this user need, bench testing would
be performed to see how many tests the sensor and battery will actually perform and to
validate the accuracy of these tests the data would be assessed to see how performance is
affected over testing cycles.

Creating the Design/Brainstorming
During the first semester, the idea was to design a blood ammonia diagnostic
device similar to a glucose meter, but over time this idea evolved into a device that would
measure breath ammonia similar to a breathalyzer. Initially, the first design was a tube
with a chemical in it that is known to react with ammonia. The tube would have valves
similar to the tricuspid valve in the heart in the sense that it would only open one way to
allow the breath to flow through, but for no reagent to come out. Nessler’s reagent was
originally chosen since it reacted with ammonia and changed fluorescence based on the
concentration of ammonia. After use, the reagent would be contaminated, so a pod
cartridge system would be utilized so that the main device could be reused while only the
pods had to be replaced. The idea was to calibrate this device with known concentrations
of ammonia and capture the intensity of the fluorescence with a good imaging system.
With these known fluorescence intensities in the system, patients could blow into the
tube, let it react and image the tube and let the software tell them the levels. However,
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this whole process has been a learning experience, and we would be remiss if we didn’t
mention that we followed our adviser’s advice and in fact “failed often and failed fast.”
The first problem that we ran into when trying to make this idea work was when we got
the full information on Nessler’s Reagent. As it turns out, Nessler’s Reagent is extremely
toxic. We moved on to other designs due to difficulties in handling the chemical and the
possibility of inhalation of the chemical when breathing into the tube.
Trying to steer away from using chemicals due to problems in handling and
disposal, we looked into actual blood alcohol concentration (BAC) readers also known as
breathalyzers. After picking a breathalyzer apart, the components and circuitry were
analyzed, helping us realize that we could revamp existing breathalyzer technology from
detecting alcohol to ammonia. The current prototype consists of an Arduino board, an
LCD screen, an MQ-137 Ammonia sensor, a 6” x 6” 3D printed box, and a rechargeable
battery. The device is shown in Figure 10 and Figure 11.

Figure 10: Ammonia-lyzer Consumer View

32

Figure 11: Ammonia-lyzer Circuit and LCD

At the core of a breathalyzer was essentially a basic circuit that was hooked up to
an MQ alcohol sensor. This is a simple gas sensor that when in the presence of alcohol
conductivity of the sensor rises along with the rising gas concentration. To our advantage,
we found that MQ ammonia sensors also exist. This would allow the detection of
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ammonia by measuring the changes in conductivity. Tutorials were discovered on how to
create an alcohol breathalyzer using an alcohol gas sensor and an Arduino board for the
circuitry. Because the schematics for a traditional 6 pin MQ sensor are the same between
the alcohol and ammonia sensor, we were able to follow along with these tutorials. Figure
12 details the circuitry schematics.
The sensor requires two voltage inputs, a heater voltage, and a circuit voltage. The
heater voltage is used to supply standard working temperatures to the sensor and can be
adopted with DC or AC power, while VRL is the voltage of the load resistance, RL,
which is in series with the sensor. The circuit voltage supplies the detection voltage to the
load resistance and adopts the DC power. Figure 4 displays the resistivity of the sensor in
measuring ammonia. In Figure 4, the Y-Axis is the resistance ratio of the sensor and the
X-Axis is the varying concentration of gasses. [33]

Figure 12: MQ-137 Test Circuit [33]
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Figure 13: NH3 Sensitivity Curve [33]

Risk Management Plan
As previously mentioned, one of the user needs was safety. For any medical
device, a Risk Management Plan along with a Failure Modes And Effects Analysis
(FMEA) should be completed to ensure that everything that can go wrong is accounted
for and assessed. The product might get misused by the consumer, so it is vital to design
out all of the possible ways the device could fail or be misused so that the patient won’t
end up getting harmed. While we were completing these documents before finishing the
prototype, we tried to come up with all the ways we thought the device could fail.
However, if testing were to be conducted on the prototype, many more failures would
probably present themselves. The Risk Management Plan, which can be found in
Appendix G, was very helpful in considering things that could potentially go wrong and
as a result, hurt the consumer or give inaccurate information. The document asked
prompting questions to allow us to analyze how the device could be misused or how it
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could fail due to components, user error, design error, environmental factors, and
manufacturing.
After developing the Risk Management Plan, the next task was to perform a
Failure Modes and Effects Analysis. This FMEA document can be found in Appendix H.
In this document, the potential mode of failure and possible causes are outlined along
with controls in place to prevent the cause or failure mode. The effects of the failure are
ranked by how severe the impact is to the product or consumer from one to five using
Table 2. The occurrences are also quantified using Table 3 to determine how often this
failure occurs. The severity and occurrence rankings are then multiplied to come up with
a risk index as shown in Table 4 where the failures are then ranked. The higher risk
indexes should be an initial point of concern and actions should be taken to reduce the
risk indexes.

Table 2: Failure Mode Effect Analysis Severity Rankings
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Table 3: Failure Mode Effect Analysis Occurrence Rankings

Table 4: Failure Mode Effect Analysis Risk Index Rankings

While we have developed potential risks that may arise during the use of our
product, Ammonia-lyzer, we are unable to comment on the FMEA occurrence and
severity of these risks as we have not entered the testing phase of our device yet.
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However, we believe that the risks we’ve identified carry little to no safety concern to the
user. The primary risks identified pertain to the small lithium-ion battery, as with any case
of lithium-ion batteries pose flammability issues. However, we have designed our product
with this in mind and developed a special enclosure for the battery within the housing to
address potential overheating.
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Future developments for viability
One of the problems we ran into was after ordering the MQ-137 ammonia sensor.
When trying to figure out how to write the program to convert the sensor's electrical
output to a numerical ammonia concentration, the datasheet was consulted again. It was
noticed that the sensor had a range of 5-500 parts per million (ppm). Ppm can be
expressed as mg/L, so the range would be from 5-500 mg/L of ammonia. The molar mass
of NH3, which is 17.031 g/mol, was used along with standard g to mg and mol to µmol
conversions making the conversion from ppm to µmol/L which are the standard units for
measuring ammonia both in the breath and blood. The simplified conversion rate is 1
ppm equals 58.71 µmol/L. It was determined that the sensor measured 293.58 µmol/L at
the lowest possible range which was originally 5 ppm. Seeing as how breath ammonia
ranges start at 50 ppb, this sensor would not be able to measure the ammonia in the
breath. This sensor might give a reading when the exhaled breath is inputted, but it will
not be reliable at all.
After realizing this, ammonia sensors with a lower minimum range were
considered. One was found that measures 0-500 PPM; however it was $637 [34] and
would take a while to be shipped. Figuring out that the sensor had a similar pin
configuration, the plan was revised. Due to limited funds and time constraints, the new
strategy would be to go ahead and construct the device with the MQ-137 sensor with a
range of 5-500 ppm. Then large amounts of ammonia that are within the 5 - 500 ppm
range with known concentrations would be inputted into the sensor. If the test levels
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show correct concentrations from the input, it is known that the rest of the components in
the device can be assumed to be working properly together. If it worked with testing
larger amounts within the range of the MQ-137 sensor, the next plan would be to order a
new sensor with a lower minimum range, preferably one that reads ppb, and change it out
with the one with the 5-500 ppm range. Additional testing would need to be completed to
ensure that this change in the sensor didn’t drastically affect the performance of the
device.
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Future Developments to Increase Scope
While the initial goal was to get a working prototype for a breath ammonia
diagnostic device, there are ways the device could be improved for added benefit. The
prototype that is currently in development has no place to internally store the results of
each test after the test is completed, and the device is turned off. The ammonia reading
would need to be written down by the consumer if they wanted to keep track of it. The
future goal of this project would be to create an app that could be interfaced with the
device. This would provide a convenient place for data to be collected and tracked over
time. Additional features of this app could include diet, medication, and behavioral
activity to be tracked as well to try to pinpoint a root cause if levels do start to rise. This
information could also be automatically sent to doctors if levels get out of range ensuring
that treatment could begin almost immediately instead of having to book an appointment
and drive to the hospital to get blood drawn. It would help catch rises in ammonia before
levels got to a point where hospital intervention had to take place to treat
hyperammonemia. Instead, a patient and doctor could be notified when levels start to rise,
ensuring that a sick day plan could begin immediately instead of waiting until the levels
increase a couple of days later when the patient starts to present early symptoms to start
treatment. It would help catch rises in ammonia before levels got to a point where
hospital intervention had to take place to treat hyperammonemia.
If this app were developed and used alongside this breath ammonia testing device,
it could provide valuable insight into how to prevent hyperammonemic episodes
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altogether. A centralized database of medications, diets, behavioral activities, and how
those activities correlate with the levels of ammonia could be used to better understand
how all of these factors come together and integrate into causing or preventing
hyperammonemic episodes.
In today's age of technology, healthcare information can be easily shared by
patients and doctors making treatment easier than ever; however, with that comes certain
considerations that need to be taken into account. Because medical information is
extremely sensitive, it needs to be handled with care. With increases in technology,
hacking has also become prevalent. This app would need to be designed to prevent not
only hacking into logged patient data but prevent them from hacking into the app and
changing the test results.
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Conclusion
Elevated ammonia levels pose a significant health risk and can be potentially
fatal. From liver disease to various metabolic disorders, systemic ammonia issues must be
continually and effectively monitored in real-time. Nonetheless, the lack of effective
diagnostics outside of the hospital is especially alarming. In an era where blood pressure,
glucose levels, heart rate, and VO2 max levels can be tested at home with minimal costs,
ammonia level testing must rid itself of the complexity and cost from the bureaucracy of
the American healthcare system. Existing blood ammonia testing diagnostics are
complicated and not viable for point-of-care or high-volume testing. The human breath
contains an abundance of analytes and data to measure health, and its non-invasive nature
will allow for easier detection and faster ascertaining of clinical decisions. While current
breath testing technology will require further research to perfect ammonia sensors, it is of
utmost importance to bridge this gap in the medical device industry for the well-being of
all.
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